J Musaazi1, A N Kiragga1, B Castelnuovo1, A Kambugu1, J Bradley2, A M Rehman2. 1. Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. 2. Medical Research Council Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Abstract
Setting: Government health centres and hospitals (six urban and 20 rural) providing tuberculosis (TB) treatment for people living with the human immunodeficiency virus (PLHIV) in central and western Uganda. Objective: To identify and quantify modifiable factors that limit TB treatment success among PLHIV in rural Uganda. Design: A retrospective cross-sectional review of routine Uganda National Tuberculosis and Leprosy Programme clinic registers and patient files of HIV-positive patients who received anti-tuberculosis treatment in 2014. Results: Of 191 rural patients, 66.7% achieved treatment success compared to 81.1% of 213 urban patients. Adjusted analysis revealed higher average treatment success in urban patients than in rural patients (OR 3.95, 95%CI 2.70-5.78, P < 0.01, generalised estimating equation model). Loss to follow-up was higher and follow-up sputum smear results were less frequently recorded in TB clinic registers among rural patients. Patients receiving treatment at higher-level facilities in rural settings had greater odds of treatment success, while patients receiving treatment at facilities where drug stock-outs had occurred had lower odds of treatment success. Conclusion: Lower reported treatment success in rural settings is mainly attributed to clinic-centred factors such as treatment monitoring procedures. We recommend strengthening treatment monitoring and delivery.
Setting: Government health centres and hospitals (six urban and 20 rural) providing tuberculosis (TB) treatment for people living with the human immunodeficiency virus (PLHIV) in central and western Uganda. Objective: To identify and quantify modifiable factors that limit TB treatment success among PLHIV in rural Uganda. Design: A retrospective cross-sectional review of routine Uganda National Tuberculosis and Leprosy Programme clinic registers and patient files of HIV-positive patients who received anti-tuberculosis treatment in 2014. Results: Of 191 rural patients, 66.7% achieved treatment success compared to 81.1% of 213 urban patients. Adjusted analysis revealed higher average treatment success in urban patients than in rural patients (OR 3.95, 95%CI 2.70-5.78, P < 0.01, generalised estimating equation model). Loss to follow-up was higher and follow-up sputum smear results were less frequently recorded in TB clinic registers among rural patients. Patients receiving treatment at higher-level facilities in rural settings had greater odds of treatment success, while patients receiving treatment at facilities where drug stock-outs had occurred had lower odds of treatment success. Conclusion: Lower reported treatment success in rural settings is mainly attributed to clinic-centred factors such as treatment monitoring procedures. We recommend strengthening treatment monitoring and delivery.
Authors: Jennifer M Ross; Adithya Cattamanchi; Cecily R Miller; Andrew J Tatem; Achilles Katamba; Priscilla Haguma; Margaret A Handley; J Lucian Davis Journal: Am J Trop Med Hyg Date: 2015-07-27 Impact factor: 2.345
Authors: Douglas N Shaffer; Eunice T Obiero; Josphat B Bett; Ignatius N Kiptoo; Jonah K Maswai; Fredrick K Sawe; E Jane Carter Journal: AIDS Res Treat Date: 2012-02-16
Authors: Joseph Baruch Baluku; Resty Nanyonjo; Jolly Ayo; Jehu Eleazer Obwalatum; Jane Nakaweesi; Catherine Senyimba; Deus Lukoye; Joseph Lubwama; Jennifer Ward; Barbara Mukasa Journal: BMC Public Health Date: 2022-04-05 Impact factor: 3.295
Authors: Jonathan Izudi; Daniel Semakula; Richard Sennono; Imelda K Tamwesigire; Francis Bajunirwe Journal: BMJ Open Date: 2019-09-06 Impact factor: 2.692
Authors: Simon Mutembo; Jane N Mutanga; Kebby Musokotwane; Cuthbert Kanene; Kevin Dobbin; Xiaobai Yao; Changwei Li; Vincent C Marconi; Christopher C Whalen Journal: BMC Infect Dis Date: 2019-12-30 Impact factor: 3.090